Clinical trial · Observational
Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma
Integrating Longitudinal Biomarker Dynamics With Clinical Features for Prognostic Prediction in Hepatocellular Carcinoma
NCT07204262CI-TRIAL-00096130completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate whether tracking changes in key blood markers over time, together with clinical features, can improve the prediction of outcomes in patients with hepatocellular carcinoma (HCC). By developing a trajectory-based prognostic model, we aim to provide more accurate risk assessment and support personalized treatment decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC) | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Advanced HCC Cohort
- description
- This cohort includes patients with advanced hepatocellular carcinoma (HCC) who received systemic therapy with molecular targeted agents (TKIs or anti-VEGF antibodies) and/or PD-(L)1 inhibitors, with or without interventional treatments such as transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC). Clinical, radiological, and laboratory data were collected retrospectively to evaluate longitudinal biomarker trajectories and construct prognostic models.
- interventionNames
- Combination Product: Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)
Primary outcomes (1)
- measure
- Objective Progression-Free Survival (PFS)
- timeFrame
- Up to approximately 3 years
- description
- To analyse the Progression-Free Survival (PFS) of patients
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. pathologically or radiologically confirmed HCC; 2. availability of pre- treatment clinical record, radiological and hematological data and more than 2 cycles of post-treatment data; 3. receipt of treatment during the study period; 4. Age rather than 18 years old. Exclusion Criteria: 1. baseline data missed; 2. Non-primary liver cancer; 3. incomplete follow-up data; 4. Unevaluable lesions.
References
Publications (0)
Data not yet available
No reference posted for this study.